Followers | 55 |
Posts | 2608 |
Boards Moderated | 0 |
Alias Born | 02/04/2014 |
Wednesday, December 30, 2015 5:12:04 PM
SOURCE Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
John S. Kovach M.D., founder and president of Lixte, said "LB-100 is a novel small molecule that in preclinical studies has activity against a number of different cancer types alone and, most prominently, in combination with cytotoxic drugs, including some known to be active against hepatocellular carcinoma. We welcome an opportunity to work with an outstanding group of investigators in Taiwan to assess the value of LB-100 against this all-too-common and devastating cancer."
HCC is the fifth most common cancer and third most common cause of cancer deaths worldwide, with the majority of those deaths in Asia. The World Cancer Research Fund International reported that 782,000 new cases were diagnosed in 2012 worldwide. There are approximately 35,000 new cases and 24,000 deaths from HCC annually in the US according to the National Cancer Institute.
Taipei Medical University has nine colleges, thirteen undergraduate schools, fifteen graduate institutes, as well as three affiliated hospitals with approximately three thousand beds. TMU is one of the largest health care systems in Taipei, providing teaching, research and clinical services. In 2012 they established the Taipei Cancer Center, the first world-class cancer center in Taiwan, combining cancer research, training and clinical treatment, dedicated to providing the full spectrum of services for adult and pediatric oncology.
http://www.newson6.com/story/30852953/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-compound-lb-100-for-potential-treatment-of-hepatocellular
Recent LIXT News
- LIXTE Receives U.S. Patent Issue Notification for Immune Oncology • GlobeNewswire Inc. • 09/04/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:05:14 PM
- First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company • GlobeNewswire Inc. • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 09:17:22 PM
- LIXTE Biotechnology Provides Update On Recent Activities and Developments • GlobeNewswire Inc. • 08/19/2024 12:30:00 PM
- LIXTE Biotechnology Holdings to Present at Two Investor Conferences • GlobeNewswire Inc. • 08/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:06:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 05:55:35 PM
- LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 03:00:00 PM
- LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 01:30:00 PM
- Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer • GlobeNewswire Inc. • 06/03/2024 12:30:00 PM
- LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” • GlobeNewswire Inc. • 05/08/2024 01:25:00 PM
- Mixed Shelf Filing Gives Micro Cap Delayed Boost • AllPennyStocks.com • 04/24/2024 07:25:00 PM
- Biotech Steals The Show Following Pre-Clinical Data Announcement • AllPennyStocks.com • 03/27/2024 07:35:00 PM
- NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:59:41 PM
- Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 03:48:13 PM
- LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI • GlobeNewswire Inc. • 02/26/2024 01:30:00 PM
- First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM